An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS
Acute respiratory distress syndrome (ARDS) is a common critical respiratory disease with a high mortality rate that has been sustained for many years and is caused by a variety of intrapulmonary and extrapulmonary pathogenic factors. However, the effective clinical interventions for ARDS currently i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Materials & Design |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0264127524001837 |
| _version_ | 1797256442263109632 |
|---|---|
| author | Sheng Li Wanshi Chen Yuhua Zhong Di Qi Yiwen Tan Renzi Zhang Daoxin Wang |
| author_facet | Sheng Li Wanshi Chen Yuhua Zhong Di Qi Yiwen Tan Renzi Zhang Daoxin Wang |
| author_sort | Sheng Li |
| collection | DOAJ |
| description | Acute respiratory distress syndrome (ARDS) is a common critical respiratory disease with a high mortality rate that has been sustained for many years and is caused by a variety of intrapulmonary and extrapulmonary pathogenic factors. However, the effective clinical interventions for ARDS currently in use mainly involve respiratory and organ support therapy, and no effective targeted drug intervention is beneficial for patients with ARDS. In the present study, GALA-PFD-Lip were constructed to reduce lung inflammation, reduce lung oxidative stress, inhibit endothelial-to-mesenchymal transition (EndMT), and reduce early pulmonary fibrosis. We found that GALA-PFD-Lip have efficacious lung targeting activity and biosafety, and the anti-inflammatory and antifibrotic effects of GALA-PFD-Lip are superior to those of pure PFD. These results suggest that GALA-PFD-Lip has good clinical translation potential for the treatment of ARDS-induced pulmonary infections. This study provides new ideas for the treatment of inflammation and for the prevention of early progressive fibrosis that is characteristic of ARDS. |
| first_indexed | 2024-03-07T16:54:11Z |
| format | Article |
| id | doaj.art-cc67b318f9f84cb09a46898bd090aa13 |
| institution | Directory Open Access Journal |
| issn | 0264-1275 |
| language | English |
| last_indexed | 2024-04-24T22:21:48Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials & Design |
| spelling | doaj.art-cc67b318f9f84cb09a46898bd090aa132024-03-20T06:08:27ZengElsevierMaterials & Design0264-12752024-03-01239112811An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDSSheng Li0Wanshi Chen1Yuhua Zhong2Di Qi3Yiwen Tan4Renzi Zhang5Daoxin Wang6Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Cardiology, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Pathology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; Corresponding authors.Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; Corresponding authors.Acute respiratory distress syndrome (ARDS) is a common critical respiratory disease with a high mortality rate that has been sustained for many years and is caused by a variety of intrapulmonary and extrapulmonary pathogenic factors. However, the effective clinical interventions for ARDS currently in use mainly involve respiratory and organ support therapy, and no effective targeted drug intervention is beneficial for patients with ARDS. In the present study, GALA-PFD-Lip were constructed to reduce lung inflammation, reduce lung oxidative stress, inhibit endothelial-to-mesenchymal transition (EndMT), and reduce early pulmonary fibrosis. We found that GALA-PFD-Lip have efficacious lung targeting activity and biosafety, and the anti-inflammatory and antifibrotic effects of GALA-PFD-Lip are superior to those of pure PFD. These results suggest that GALA-PFD-Lip has good clinical translation potential for the treatment of ARDS-induced pulmonary infections. This study provides new ideas for the treatment of inflammation and for the prevention of early progressive fibrosis that is characteristic of ARDS.http://www.sciencedirect.com/science/article/pii/S0264127524001837ARDSEndMTLung-targeting peptideLipid nanoparticlesPFDInflammation |
| spellingShingle | Sheng Li Wanshi Chen Yuhua Zhong Di Qi Yiwen Tan Renzi Zhang Daoxin Wang An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS Materials & Design ARDS EndMT Lung-targeting peptide Lipid nanoparticles PFD Inflammation |
| title | An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS |
| title_full | An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS |
| title_fullStr | An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS |
| title_full_unstemmed | An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS |
| title_short | An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS |
| title_sort | application of pirfenidone loaded lung targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ards |
| topic | ARDS EndMT Lung-targeting peptide Lipid nanoparticles PFD Inflammation |
| url | http://www.sciencedirect.com/science/article/pii/S0264127524001837 |
| work_keys_str_mv | AT shengli anapplicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT wanshichen anapplicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT yuhuazhong anapplicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT diqi anapplicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT yiwentan anapplicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT renzizhang anapplicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT daoxinwang anapplicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT shengli applicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT wanshichen applicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT yuhuazhong applicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT diqi applicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT yiwentan applicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT renzizhang applicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards AT daoxinwang applicationofpirfenidoneloadedlungtargetednanoliposomesfortreatinginflammationandearlypulmonaryfibrosisinards |